Having posted positive returns in July in nine of the last 10 years, with an average July return of 4.8%, the medical devices and health… Read More »This Pharma Stock Has A Great Record Of Returns In July
The final week of January was yet another big one for biotech, with perhaps the most important development of the week being phase III trial results for Novavax’s COVID-19 vaccine.
Of the two “best of both worlds” biotech stocks highlighted in today’s article – “companies with both solid drug-development track records and potential COVID-19 vaccine tailwinds that could net them each significant profits for their role over the next several years”.
While the surge in interest in pharmaceutical stocks this year has been primarily driven by factors related to the COVID-19 pandemic, the author of today’s article advises that “companies working on pharmaceutical products for unmet needs or other niche markets such as animal health could be worth a closer look.”
A trio of biotech firms IPOed on Friday – and saw double-digit gains on their trading debuts.
Regarding investor behavior amid the current market volatility, the author of today’s article observes that “A select group remains ready to take on some risk,… Read More »3 “Strong Buy” Pharma Stocks With Significant Upside Potential – And Catalysts Around The Corner